Medprin Regenerative Medical Technologies Co., Ltd. (SHE:301033)
China · Delayed Price · Currency is CNY 54.15
+0.54 (1.01%)
At close: Sep 4, 2026
SHE:301033 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,612 | 4,502 | 2,782 | 2,876 | 2,436 | 4,038 | |
Market Cap Growth | -28.31% | 61.81% | -3.27% | 18.06% | -39.66% | - |
Enterprise Value | 3,338 | 4,247 | 2,604 | 2,737 | 2,281 | 3,756 |
Last Close Price | 54.15 | 66.55 | 41.07 | 42.09 | 35.50 | 58.66 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 29.78 | 39.80 | 35.28 | 70.37 | 67.88 | 90.30 |
Forward PE | - | 46.68 | 40.83 | 46.57 | - | - |
PS Ratio | 9.01 | 12.21 | 9.99 | 12.46 | 12.48 | 26.26 |
PB Ratio | 4.45 | 5.64 | 3.98 | 4.52 | 4.04 | 7.01 |
P/TBV Ratio | 4.83 | 6.17 | 4.37 | 5.08 | 4.42 | 7.80 |
P/FCF Ratio | 37.51 | 38.80 | 33.43 | 42.55 | - | - |
P/OCF Ratio | 27.45 | 32.19 | 23.91 | 26.71 | 50.43 | 60.71 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 8.33 | 11.51 | 9.35 | 11.85 | 11.68 | 24.43 |
EV/EBITDA Ratio | 21.21 | 29.75 | 24.88 | 40.18 | 58.51 | 113.22 |
EV/EBIT Ratio | 25.61 | 36.46 | 32.97 | 61.91 | 88.62 | 139.08 |
EV/FCF Ratio | 34.68 | 36.60 | 31.29 | 40.48 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | - | 0.00 | 0.08 | 0.14 | 0.19 |
Debt / EBITDA Ratio | 0.06 | - | 0.01 | 0.76 | 2.00 | 3.15 |
Debt / FCF Ratio | 0.10 | - | 0.01 | 0.79 | - | - |
Net Debt / Equity Ratio | -0.34 | -0.38 | -0.36 | -0.26 | -0.18 | -0.48 |
Net Debt / EBITDA Ratio | -1.75 | -2.14 | -2.38 | -2.44 | -2.83 | -8.30 |
Net Debt / FCF Ratio | -2.84 | -2.63 | -2.99 | -2.46 | 1.26 | 3.19 |
Asset Turnover | 0.47 | 0.44 | 0.35 | 0.30 | 0.26 | 0.26 |
Inventory Turnover | 2.10 | 2.12 | 1.91 | 1.50 | 1.24 | 1.45 |
Quick Ratio | 8.16 | 6.44 | 5.80 | 3.51 | 2.49 | 7.25 |
Current Ratio | 9.47 | 7.28 | 6.58 | 3.96 | 2.91 | 7.70 |
Return on Equity (ROE) | 16.02% | 15.11% | 11.81% | 6.60% | 6.07% | 9.76% |
Return on Assets (ROA) | 9.55% | 8.59% | 6.22% | 3.61% | 2.16% | 2.83% |
Return on Invested Capital (ROIC) | 21.71% | 22.15% | 14.52% | 7.83% | 5.81% | 9.95% |
Return on Capital Employed (ROCE) | 15.10% | 13.80% | 10.50% | 6.10% | 3.90% | 3.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.39% | 2.51% | 2.83% | 1.42% | 1.47% | 1.11% |
FCF Yield | 2.67% | 2.58% | 2.99% | 2.35% | -3.60% | -2.14% |
Dividend Yield | 1.31% | 1.05% | 1.46% | 0.95% | 0.56% | 0.17% |
Payout Ratio | 38.21% | 35.09% | 34.41% | 37.38% | 22.43% | - |
Buyback Yield / Dilution | -2.03% | -1.87% | 0.33% | 0.80% | -17.43% | -14.83% |
Total Shareholder Return | -0.72% | -0.82% | 1.79% | 1.75% | -16.87% | -14.66% |